Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
24-Dehydrocholesterol reductase (DHCR24), also known as seladin-1, is a flavin adenine dinucleotide (FAD)-dependent oxidoreductase located in the endoplasmic reticulum. It catalyzes the final step of cholesterol biosynthesis, specifically the reduction of the delta-24 double bond of sterol intermediates, such as the conversion of desmosterol to cholesterol. Beyond its role in lipid metabolism, DHCR24 is involved in protecting cells from oxidative stress and apoptosis, and it plays a critical role in maintaining the integrity of cholesterol-rich membrane microdomains (lipid rafts). Altered expression of DHCR24 is implicated in several pathological conditions; its downregulation is associated with Alzheimer's disease and neurodegeneration, whereas its overexpression is observed in various cancers, including melanoma and adrenal gland cancer. Pharmacological inhibition of DHCR24, using drugs like triparanol or the selective inhibitor SH42, leads to the accumulation of desmosterol, which acts as an endogenous agonist of the liver X receptor (LXR) to promote anti-inflammatory and pro-resolving phenotypes. However, therapeutic targeting of DHCR24 carries significant safety challenges, as complete or systemic inhibition can disrupt cholesterol homeostasis, leading to adverse effects such as cataracts, skin disorders, and developmental abnormalities similar to the genetic disorder desmosterolosis.
Inhibition of 24-dehydrocholesterol reductase (DHCR24) blocks the terminal step of cholesterol biosynthesis, preventing the conversion of desmosterol to cholesterol. This leads to the accumulation of desmosterol, which acts as an endogenous agonist of the liver X receptor (LXR), triggering anti-inflammatory and lipid-reprogramming pathways. Alternatively, in cancer, inhibition of DHCR24 reduces cholesterol levels and disrupts lipid raft formation, thereby suppressing tumor cell proliferation and migration.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 24-dehydrocholesterol reductase (DHCR24).